Zhende Medical(SH:603301) Zheng Quan Zhi Xing·2025-05-09 08:45Meeting Agenda - The 2024 Annual General Meeting of Shareholders will cover various reports including the independent director's report, financial settlement report, profit distribution proposal, and proposals for foreign exchange trading and credit limits for subsidiaries [1][2][3] Company Performance - In 2023, the company achieved a revenue of 4.264 billion yuan, a 3.32% increase year-on-year, with a net profit attributable to shareholders of 385 million yuan, a 94.14% increase [4][5] - The revenue from isolation protective products was 160 million yuan, a decrease of 4.23 billion yuan year-on-year, while excluding these products, the revenue grew by 15.80% [4][5] Market Strategy - The company focuses on core areas such as surgical infection control and rehabilitation, enhancing market competitiveness through strategic planning and operational efficiency [6][7] - The company has expanded its coverage to nearly 9,000 hospitals across China, with over 1,200 being top-tier hospitals [6] Retail Market Development - The company has achieved a retail revenue of 594 million yuan, with a 9.77% increase year-on-year when excluding isolation protective products [8] - The company has established a strong presence in both online and offline retail channels, covering 99% of the top 100 pharmacy chains in China [7][8] International Expansion - The company is actively developing production bases in Africa and Mexico to enhance its international market competitiveness and meet diverse supply chain needs [9][10] - The overseas revenue reached 2.475 billion yuan, a 14.64% increase year-on-year, driven by strong performance in Southeast Asia and the Middle East [10] Research and Development - The company has focused on innovative product development in areas such as wound care and infection control, with significant investments in R&D [11][12] - The company has obtained 9 new medical device registrations and 28 patents, totaling 105 patents and 136 medical device registrations [12] Governance and Compliance - The board of directors has adhered to legal regulations and company bylaws, ensuring compliance and effective decision-making [19][20] - The company has implemented a profit distribution plan, distributing a total of 133.16 million yuan in cash dividends [21] Future Plans - The company aims to enhance its governance structure, expand market penetration, and strengthen R&D investments in 2025 [22][23] - The company will focus on product strategy, brand building, and digital transformation to improve operational efficiency and market presence [24][25]